Liposomal Docetaxel for Agricultural, Veterinary, and Aquatic Applications
Legal Citation
Summary of the Inventive Concept
The present inventive concept relates to novel applications of liposomal docetaxel compositions for pest control, fungal disease treatment, and cancer treatment in various industries, including agriculture, veterinary medicine, and aquaculture.
Background and Problem Solved
The original patent disclosed a liposomal composition of docetaxel for cancer treatment, but its potential uses were limited to the pharmaceutical industry. The present inventive concept addresses the need for innovative solutions in other industries, where the unique properties of liposomal docetaxel can provide effective and targeted treatments.
Detailed Description of the Inventive Concept
The new claims describe liposomal compositions of docetaxel tailored for specific industries, including agricultural pest control, veterinary cancer treatment, and aquatic disease treatment. These compositions leverage the original patent's high drug loading and targeting capabilities, while incorporating industry-specific requirements, such as pH adjustments and solubilizers. The inventive concept encompasses systems and methods for delivering docetaxel to pests, plants, companion animals, and aquatic organisms, offering a range of benefits, including increased efficacy, reduced toxicity, and improved environmental sustainability.
Novelty and Inventive Step
The new claims introduce novel applications of liposomal docetaxel, which were not contemplated in the original patent. The inventive step lies in the adaptation of the original composition to new industries, requiring specific modifications and optimizations to address distinct challenges and needs.
Alternative Embodiments and Variations
Alternative embodiments may include varying the liposomal composition's pH, solubilizers, or docetaxel concentrations to suit different industries or specific use cases. Variations could also involve incorporating additional components, such as targeting moieties or synergistic agents, to enhance the composition's efficacy or selectivity.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the agricultural, veterinary, and aquaculture industries, offering innovative solutions for pest control, disease treatment, and cancer therapy. The target market includes companies involved in crop protection, animal health, and aquaculture, as well as research institutions and government agencies focused on sustainable and environmentally friendly practices.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K9/127 |
| A | A61 | A61K9/0019 |
| A | A61 | A61K9/1277 |
| A | A61 | A61K31/337 |
| A | A61 | A61K47/24 |
| A | A61 | A61K47/26 |
| A | A61 | A61K47/28 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical formulation and drug delivery systems, specifically liposomal drug compositions with a focus on targeted therapeutic applications across multiple biological domains
Person of Ordinary Skill (PHOSITA) Profile
A pharmaceutical scientist with expertise in liposomal drug formulation, having advanced degrees in pharmaceutical sciences or chemical engineering, with knowledge of drug encapsulation techniques, pH modulation, and targeted delivery systems
Obviousness Rationale
A person having ordinary skill in the art would recognize that the source patent's liposomal docetaxel composition provides a foundational template that can be readily adapted to different application domains by making predictable modifications to pH, concentration, and delivery mechanisms. The core liposomal technology disclosed in the source patent inherently suggests potential cross-industry applications by demonstrating high drug loading and targeted delivery capabilities. The variations proposed in the PTD represent logical extensions of the original formulation principles using standard pharmaceutical engineering techniques.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,680 |
|---|---|
| Title | Composition of docetaxel liposomal injection with high drug loading |
| Assignee(s) | SHILPA MEDICARE LIMITED |